Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

by Dutta, Lea , Merchan, Jaime R , Rha, Sun-Young , Melichar, Bohuslav , Rolland, Frederic , Hong, Sung-Hoo , Alyasova, Anna , Kim, Miso , Porta, Camillo , Méndez-Vidal, María J , Choueiri, Toni K , Xing, Dongyuan , Gurney, Howard , Bedke, Jens , Patel, Vijay , Takagi, Toshio , Alekseev, Boris , Maroto, Pablo , Kozlov, Vadim , Dutcus, Corina E , Kapoor, Anil , Powles, Thomas , Wong, Shirley , Grünwald, Viktor , Goh, Jeffrey C , Procopio, Giuseppe , Alonso Gordoa, Teresa , Peer, Avivit , Perini, Rodolfo F , Mody, Kalgi , Motzer, Robert , Hutson, Thomas E , Kopyltsov, Evgeny , Schmidinger, Manuela , Smith, Alan D , Eto, Masatoshi , De Giorgi, Ugo , Winquist, Eric

in Adult / Adverse events / Aged / Aged, 80 and over / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antineoplastic Agents / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Apoptosis / Carcinoma, Renal Cell / Carcinoma, Renal Cell - drug therapy / Carcinoma, Renal Cell - mortality / Confidence intervals / Diarrhea / Drug dosages / Everolimus / Everolimus - administration & dosage / Everolimus - adverse effects / Female / General Medicine / Human health sciences / Humans / Immunotherapy / Inhibitor drugs / Kidney cancer / Kidney Neoplasms / Kidney Neoplasms - drug therapy / Kidney Neoplasms - mortality / lenvatinib / Male / Medicine (all) / Middle Aged / Monoclonal antibodies / Oncologie / Oncology / Pembrolizumab / Phenylurea Compounds / Phenylurea Compounds - administration & dosage / Phenylurea Compounds - adverse effects / Programmed Cell Death 1 Receptor / Programmed Cell Death 1 Receptor - antagonists & inhibitors / Progression-Free Survival / Protein Kinase Inhibitors / Protein Kinase Inhibitors - therapeutic use / Quinolines / Quinolines - administration & dosage / Quinolines - adverse effects / Renal cell carcinoma / Sciences de la santé humaine / Solid tumors / Statistical analysis / Sunitinib / Sunitinib - adverse effects / Sunitinib - therapeutic use / Survival Analysis / Targeted cancer therapy

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

2021

Confirm

Do you wish to request the book?

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Dutta, Lea,

Merchan, Jaime R,

Rha, Sun-Young,

Melichar, Bohuslav,

Rolland, Frederic,

Hong, Sung-Hoo,

Alyasova, Anna,

Kim, Miso,

Porta, Camillo,

Méndez-Vidal, María J,

Choueiri, Toni K,

Xing, Dongyuan,

Gurney, Howard,

Bedke, Jens,

Patel, Vijay,

Takagi, Toshio,

Alekseev, Boris,

Maroto, Pablo,

Kozlov, Vadim,

Dutcus, Corina E,

Kapoor, Anil,

Powles, Thomas,

Wong, Shirley,

Grünwald, Viktor,

Goh, Jeffrey C,

Procopio, Giuseppe,

Alonso Gordoa, Teresa,

Peer, Avivit,

Perini, Rodolfo F,

Mody, Kalgi,

Motzer, Robert,

Hutson, Thomas E,

Kopyltsov, Evgeny,

Schmidinger, Manuela,

Smith, Alan D,

Eto, Masatoshi,

De Giorgi, Ugo,

Winquist, Eric

2021

Overview

Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib. Lenvatinib plus everolimus was also more effective than sunitinib, but the difference was smaller.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society,Massachussetts Medical Society

Subject

Adult

/ Adverse events

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal, Humanized

/ Antibodies, Monoclonal, Humanized - administration & dosage

/ Antibodies, Monoclonal, Humanized - adverse effects